CPECN

Piramal Pharma Solutions makes $30 million investment at third plant in Ontario

Mike Edwards   

News active pharmaceutical ingredients APIs Aurora Piramel Pharma plant investment

Piramel Pharma's third active pharmaceutical ingredient (API) plant at the company’s site in Aurora, ON, has come online and successfully completed its initial production runs.

Piramal Pharma Limited’s Pharma Solutions business, a (CDMO), has announced that a new active pharmaceutical ingredient (API) plant at the company’s site in Aurora, ON, has come online and successfully completed its initial production runs.

The new plant, built as part of a $30 million capital investment in the Aurora site, features more than ten thousand square feet of new manufacturing space and includes two new reactor suites with additional filtration and drying capabilities.

It will support ongoing customer demand for Piramal Pharma Solutions’ expertise in APIs and enhances and expands the company’s ability to produce clinical to commercial scale APIs including highly potent APIs requiring an Occupational Exposure Limit (OEL) of 1 mcg/m3.

Since coming online, the company says, the plant has successfully implemented programs for clients that include process validation campaign, a registration campaign for clinical re-supply, and an engineering campaign. There is said to be a strong customer demand for the new plant’s capacity, with a pipeline of clinical and commercial scale projects planned.

Peter DeYoung, CEO, Piramal Pharma Solutions.

Peter DeYoung, CEO of Mumbai, India-based Piramal Pharma Solutions said, “It’s exciting to see the capacity expansion at our Aurora facility in Canada begin to deliver for our clients. We’ve achieved our objectives of strengthening our presence in Canada, adding API development and commercial support for other geographies such as North America and Europe, and supporting market demand for integrated solutions.

“As a patient centric organization, this is another example of our commitment to serving the patient community and reducing the burden of disease.”

Plant 3 Reactor Suite, 4000L and 3000L Glass-lined Reactors.

With successful inspections by the US FDA, the UK MHRA and the PMDA, Piramal Pharma Solutions’ Aurora facility is said to have a stellar track record of regulatory compliance and is committed to maintaining gold standards of environmental performance, health & safety.


Print this page

Advertisement

Stories continue below